Journal of Agricultural and Food Chemistry
Article
1
a
Table 2. 13C NMR Data for 1−4 in DMSO-d6
Compound 1a. White amorphous powder; H NMR (500 MHz,
acetone-d6) δ 11.37 (1H, s, 2-OH), 7.21 (1H, dt, J = 16.7, 7.1 Hz),
7.17 (1H, dd, J = 15.3, 2.0 Hz), 6.51 (1H, d, J = 2.5 Hz, H-5), 6.44
(1H, d, J = 2.5 Hz, H-3), 6.15 (1H, d, J = 16.7 Hz), 6.07 (1H, ddd, J =
15.3, 10.1, 3.7 Hz), 5.40 (1H, m, H-10′), 5.04 (1H, d, J = 8.8 Hz, H-
5′), 4.05 (1H, ddd, J = 8.8, 4.1, 2.9 Hz, H-4′), 3.86 (3H, s, 4-OCH3),
2.82−2.91 (2H, m), 2.66 (1H, ddd, J = 15.5, 7.7, 1.2 Hz), 2.54 (1H,
ddd, J = 16.0, 10.1, 2.7 Hz), 1.47 (3H, d, J = 6.3 Hz, H-11′), 1.41 (3H,
s, H-14′), 1.37 (3H, s, H-15′); 13C NMR (acetone-d6, 125 MHz) δ
196.4 (C), 171.1 (C), 165.3 (C), 165.0 (C), 146.7 (C), 143.6 (CH),
135.8 (CH), 133.8 (CH), 127.0 (CH), 110.0 (C), 108.7 (CH), 105.7
(C), 101.0 (CH), 79.4 (CH), 77.6 (CH), 71.9 (CH), 56.0 (OCH3),
38.0 (CH2), 34.2 (CH2), 27.3 (CH3), 26.4 (CH3), 20.2 (CH3); ESIMS
m/z 403.3 [M + H]+, 425.3 [M + Na]+, 827.5 [2M + Na]+.
position
1
2
3
4
1
110.4, C
114.3, C
112.9, C
111.6, C
2
158.8, C
155.8, C
156.7, C
157.8, C
3
100.3, CH
161.8, C
100.5, CH
160.7, C
100.3, CH
161.0, C
100.1, CH
161.3, C
4
5
103.6, CH
138.9, C
100.9, CH
136.3, C
101.9, CH
137.3, C
102.6, CH
138.3, C
6
1′
2′
3′
4′
5′
6′
129.2, CH
130.7, CH
36.5, CH2
72.7, CH
75.8, CH
200.2 C
129.0, CH
131.3, CH
35.7, CH2
71.5, CH
73.6, CH
199.9, C
129.2, CH
130.5, CH
36.0, CH2
73.0, CH
78.8, CH
200.1, C
128.6, CH
130.5, CH
36.0, CH2
71.9, CH
78.2, CH
200.7, C
1
Compound 3a. White amorphous powder; H NMR (500 MHz,
acetone-d6) δ 11.60 (1H, s, 2-OH), 7.06 (1H, dt, J = 16.1, 6.2 Hz),
6.83 (1H, d, J = 15.6 Hz), 6.60 (1H, d, J = 16.1 Hz), 6.50 (1H, d, J =
2.2 Hz, H-5), 6.42 (1H, d, J = 2.2 Hz, H-3), 6.07 (1H, ddd, J = 15.6,
8.5, 5.9 Hz), 5.53 (1H, m, H-10′), 4.99 (1H, d, J = 6.7 Hz, H-5′), 4.64
(1H, ddd, J = 9.6, 6.7, 2.0 Hz, H-4′), 3.85 (3H, s, 4-OCH3), 2.86 (1H,
m), 2.70−2.60 (2H, m), 2.44 (1H, m), 1.56 (3H, s, H-15′), 1.47 (3H,
d, J = 6.5 Hz, H-11′), 1.36 (3H, s, H-14′); 13C NMR (acetone-d6, 125
MHz) δ 196.6 (C), 171.3 (C), 165.2 (C), 164.8 (C), 143.2 (C), 142.3
(CH), 134.0 (CH), 130.8 (CH), 128.6 (CH), 109.8 (C), 108.5 (C),
105.9 (CH), 100.9 (CH), 81.9 (CH), 77.9 (CH), 71.7 (CH), 55.9
(OCH3), 37.3 (CH2), 34.4 (CH2), 27.0 (CH3), 25.9 (CH3), 18.7
(CH3); ESIMS m/z 425.0 [M + Na]+.
7′
8′
9′
131.0, CH
143.9, CH
37.5, CH2
69.9, CH
19.7, CH3
167.9, C
131.3, CH
143.9, CH
37.9, CH2
70.5, CH
20.4, CH3
167.6, C
129.7, CH
142.7, CH
37.5, CH2
69.8, CH
19.9, CH3
167.6, C
130.3, CH
142.4, CH
37.9, CH2
70.2, CH
20.1, CH3
168.2, C
10′
11′
12′
4-OCH3
55.3, CH3
55.3, CH3
55.2, CH3
55.3, CH3
a
100 MHz for 1, 125 MHz for 2−4, δ in ppm.
1
Cochliomycin E (2). White amorphous powder; [α]25D −73 (c 0.10,
Compound 4a. White amorphous powder; H NMR (500 MHz,
acetone-d6) δ 11.39 (1H, s, 2-OH), 7.06 (1H, dt, J = 15.5, 7.9 Hz),
6.96 (1H, dd, J = 15.5, 2.2 Hz), 6.55 (1H, d, J = 2.6 Hz, H-5), 6.48
(1H, d, J = 15.5 Hz), 6.42 (1H, d, J = 2.6 Hz, H-3), 6.03 (1H, ddd, J =
15.5, 10.0, 3.9 Hz), 5.58 (1H, m, H-10′), 4.85 (1H, d, J = 6.6 Hz, H-
5′), 4.65 (1H, ddd, J = 10.9, 6.6, 2.6 Hz, H-4′), 3.85 (3H, s, 4-OCH3),
2.69 (1H, ddd, J = 15.7, 6.4, 2.7 Hz), 2.65−2.60 (2H, m), 2.34 (1H, dt,
J = 16.2, 10.5 Hz), 1.59 (3H, s, H-14′), 1.47 (3H, d, J = 6.5 Hz, H-
11′), 1.35 (3H, s, H-15′); 13C NMR (acetone-d6, 125 MHz) δ 196.7
(C), 171.1 (C), 165.2 (C), 164.8 (C), 143.2 (C), 142.2 (CH), 133.7
(CH), 132.1 (CH), 128.8 (CH), 109.9 (C), 109.9 (C), 108.2 (CH),
101.7 (CH), 82.3 (CH), 78.5 (CH), 72.2 (CH), 55.9 (OCH3), 37.7
(CH2), 35.3 (CH2), 27.0 (CH3), 26.0 (CH3), 19.0 (CH3); ESIMS m/z
425.0 [M + Na]+.
Preparation of Tri-p-bromobenzoyl Derivatives, 1b, 3b, and
4b. Cochliomycin D, 1 (2.0 mg), was treated with p-bromobenzoyl
chloride (15 mg) and 4-N,N-dimethylaminopyridine (DMAP, 2.5 mg)
in 1.5 mL of pyridine/CH2Cl2 (1:2) at 40 °C for 2 h. The mixture was
diluted with EtOAc and washed with H2O and 1 M NaHCO3, and the
organic layer was concentrated under a vacuum to obtain a colorless
solid. It was then purified by Sephadex LH-20 column chromatog-
raphy and semipreparative HPLC to obtain 1b (2.9 mg). Tri-p-
bromobenzoyl derivatives 3b (0.5 mg) and 4b (1.8 mg) were prepared
similarly from cochliomycin F, 3 (0.3 mg), and (7′E)-6′-oxozeaenol, 4
(1.2 mg), respectively.
MeOH); UV (MeOH) λmax (log ε) 198 (3.33), 223 (4.10), 271
(3.93), 312 (3.66) nm; CD (0.83 mM, MeOH) λmax (Δε) 220
(+5.53), 245 (+3.86), 278 (−1.99) nm; IR (KBr) νmax 3745, 3646,
1696, 1647, 1556, 1518 cm−1; 1H and 13C NMR data, see Tables 1 and
2; ESIMS m/z 385.1 [M + Na]+; HRESIMS m/z 385.1269 [M + Na]+
(calcd for C19H22O7Na, 385.1258).
Cochliomycin F (3). White amorphous powder; [α]25 −23.3 (c
D
0.10, MeOH); UV (MeOH) λmax (log ε) 198 (3.09), 231 (4.19), 271
(3.95), 312 (3.67) nm; CD (3.86 mM, MeOH) λmax (Δε) 228
(+2.20), 248 (+2.62), 274 (−1.77), 316 (+0.16) nm; IR (KBr) νmax
3747, 3648, 1700, 1650, 1556, 1521 cm−1; 1H and 13C NMR data, see
Tables 1 and 2; ESIMS m/z 385.1 [M + Na]+, 747.1 [2M + Na]+;
HRESIMS m/z 385.1268 [M + Na]+ (calcd for C19H22O7Na,
385.1258).
(7′E)-6′-Oxozeaenol (4). White amorphous powder; [α]25 −50 (c
D
0.20, MeOH) {literature [α]24 −27.0 (c 0.33, MeOH)};6 CD (0.83
D
mM, MeOH) λmax (Δε) 235 (+12.61), 273 (−6.34), 316 (−1.07), 350
1
(+0.04) nm; H and 13C NMR data, see Tables 1 and 2; ESIMS m/z
385.1 [M + Na]+, 747.2 [2M + Na]+.
LL-Z1640-2 (6). White amorphous powder; [α]25 −94 (c 0.10,
D
MeOH) {literature [α]24 −75.9 (c 0.41, MeOH)};7 CD (2.21 mM,
D
MeOH) λmax (Δε) 216 (+3.82), 247 (+7.22), 272 (−13.60), 343
(+0.71) nm.
Specific Rotation Data for Known Compounds 5 and 7−11.
deoxy-Aigialomycin C (5): [α]25 +43.3 (c 0.10, MeOH) {literature
Compound 1b. White amorphous powder; CD (0.87 mM,
D
1
[α]24 +25.4 (c 5.4, CH2Cl2)}.8 Zeaenol (7): [α]25 −79 (c 0.15,
CH2Cl2) λmax (Δε) 262 (−11.64), 242 (+11.18) nm; H NMR (500
D
D
MeOH) {literature [α]24 −92 (c 0.54, MeOH)}.9 LL-Z1640-1 (8):
MHz, CDCl3) δ 8.05 (2H, d, J = 8.5 Hz, p-bromobenzoyl), 7.90 (2H,
d, J = 8.5 Hz, p-bromobenzoyl), 7.75 (2H, d, J = 8.5 Hz, p-
bromobenzoyl), 7.66 (2H, d, J = 8.5 Hz, p-bromobenzoyl), 7.57 (2H,
d, J = 8.5 Hz, p-bromobenzoyl), 7.49 (2H, d, J = 8.5 Hz, p-
bromobenzoyl), 7.11 (1H, ddd, J = 15.5, 8.7, 5.4 Hz), 6.93 (1H, d, J =
15.5 Hz), 6.88 (1H, d, J = 2.2 Hz, H-5), 6.73 (1H, d, J = 2.2 Hz, H-3),
6.34 (1H, d, J = 16.1 Hz), 6.12 (1H, m), 5.78 (1H, d, J = 3.4 Hz), 5.77
(1H, m), 5.33 (1H, m), 3.85 (3H, s, 4-OCH3), 2.84 (1H, dt, J = 14.7,
7.4 Hz), 2.64 (2H, m), 2.42 (1H, m), 1.20 (3H, d, J = 6.3 Hz, H-11′);
ESIMS m/z 933.0 [M + Na]+.
D
[α]25 −91.7 (c 0.10, MeOH) {literature [α]24 −80 (c 0.48,
D
D
MeOH)}.7 Paecilomycin F (9): [α]25 −112.5 (c 0.04, MeOH)
D
{literature [α]24 −106.4 (c 0.28, MeOH)}.10 Cochliomycin A (10):
D
[α]25 +32.7 (c 0.10, MeOH) {literature [α]24 +10.5 (c 0.43,
D
D
MeOH)}.5 Aigialomycin B (11): [α]25 −26.7 (c 0.05, MeOH)
D
{literature [α]24 −10 (c 0.27, CHCl3)}.2
PreparationDof the Acetonide Derivatives, 1a, 3a, and 4a. A
mixture of 1 (3.0 mg), 2,2-dimethoxypropane (1.5 mL), and p-TsOH
(0.2 mg) was stirred at room temperature for 1 h. Saturated aqueous
NaHCO3 (5 mL) was then added, and the reaction mixture was
extracted with EtOAc (5 mL × 3). The organic solvents were removed
under a vacuum, and the crude mixture was subjected to semi-
preparative HPLC to obtain 1a (2.8 mg). By the same procedures, the
acetonides 3a (1.0 mg) and 4a (2.5 mg) were prepared from 3 (1.2
mg) and 4 (3.0 mg), respectively.
Compound 3b. White amorphous powder; CD (0.32 mM,
1
CH2Cl2) λmax (Δε) 276 (−0.63), 249 (+5.40) nm; H NMR (500
MHz, CDCl3) δ 8.04 (2H, d, J = 8.5 Hz, p-bromobenzoyl), 7.95 (2H,
d, J = 8.5 Hz, p-bromobenzoyl), 7.85 (2H, d, J = 8.5 Hz, p-
bromobenzoyl), 7.66 (2H, d, J = 8.5 Hz, p-bromobenzoyl), 7.61 (2H,
d, J = 8.5 Hz, p-bromobenzoyl), 7.57 (2H, d, J = 8.5 Hz, p-
3185
dx.doi.org/10.1021/jf500248z | J. Agric. Food Chem. 2014, 62, 3183−3191